Interestingly, the authors demonstrated the superior ability of EV-derived LDHC mRNA to distinguish the TNM stage I/II HCC patients from healthy controls compared with serum-only LDHC mRNA, with an AUC of 0.95 vs. 0.84, respectively [123]. This evidence concerns the gene LDHC and hepatocellular carcinoma.